About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition, the company received FDA approval for two products: Cumulase(R) and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.
This release includes forward-looking statements concerning the
companies' expectations related to the expanded relationship between
Halozyme and Baxter. The statements are based on assumptions about many
important factors, including the following, which could cause actual
results to differ materially from those in the forward-looking statements:
the anticipated timing of regulatory filings and the success of certain
regulatory events regarding gaining regulatory approval for the products
described in this release including those products under development; the
effectiveness of the products described in this release including those
products under development; the ability of Baxter to effectively capitalize
on drug-delivery platform opportunities in existing and new markets; demand
for and market acceptance for the products described in this release
including those products under development; the impact of competitive
products and pricing, including generic competition, drug re-importation
and disruptive technologies; internal and external factors that c
|SOURCE Baxter International Inc.|
Copyright©2007 PR Newswire.
All rights reserved